A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.

<h4>Background</h4>The second generation antipsychotic drugs represent the most common form of pharmacotherapy for schizophrenia disorders. It is now well established that most of the second generation drugs cause metabolic side-effects. Risperidone and its active metabolite paliperidone...

Full description

Bibliographic Details
Main Authors:	Heidi N Boyda, Ric M Procyshyn, Lurdes Tse, Jessica W Y Yuen, William G Honer, Alasdair M Barr
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0246211

Similar Items

Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
by: Heidi N. Boyda, et al.
Published: (2020-12-01)

Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance
by: Heidi N. Boyda, et al.
Published: (2022-02-01)

An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.
by: Claire Wu, et al.
Published: (2014-01-01)

A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents
by: Thomas Dodsworth, et al.
Published: (2018-07-01)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs L, et al.
Published: (2013-03-01)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
by: Lulu Lian, et al.
Published: (2022-01-01)

Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
by: Jessica W. Y. Yuen, et al.
Published: (2018-04-01)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01)

Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis.
by: Lik Hang N Lee, et al.
Published: (2018-01-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
by: Ahmad Ghanizadeh
Published: (2013-01-01)

Valproate, risperidone, and paliperidone: A case of valproate-induced hyperammonemic encephalopathy
by: Kyle Wesselman, PharmD candidate, MA, BS, et al.
Published: (2024-02-01)

Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis
by: Lik Hang N. Lee, et al.
Published: (2023-06-01)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
by: Schooler Nina, et al.
Published: (2011-02-01)

Risperidone-induced tardive akathisia: A rare antipsychotic side effect with management issues
by: Biswa Ranjan Mishra, et al.
Published: (2019-01-01)

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
by: Wentzel-Larsen Tore, et al.
Published: (2010-03-01)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
by: Zachary Orlins, et al.
Published: (2021-01-01)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
by: Rong-Qin Wu, et al.
Published: (2018-01-01)

Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension
by: Ric M Procyshyn, et al.
Published: (2020-01-01)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
by: Carlos Sch&ouml;nfeldt-Lecuona, et al.
Published: (2011-03-01)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
by: Patel, R, et al.
Published: (2017)

The impact of the COVID-19 pandemic on the trend of prescribing long-acting injections of paliperidone and risperidone in Central Serbia
by: Milena Stojkovic, et al.
Published: (2023-12-01)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
by: Zhao M, et al.
Published: (2023-04-01)

The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.
by: Meghan May, et al.
Published: (2019-01-01)

Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
by: David D. Kim, et al.
Published: (2021-05-01)

Analysis of proarrhythmic potential of an atypical antipsychotic drug paliperidone in the halothane-anesthetized dogs
by: Koki Chiba, et al.
Published: (2017-08-01)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
by: Charmi Patel, MPH, RN, et al.
Published: (2020-01-01)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
by: Gang Wang, et al.
Published: (2020-04-01)

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium
by: Rui Cai, et al.
Published: (2022-06-01)

Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
by: Lee, C., et al.
Published: (2006)

Proteinoid Nanocapsules as Drug Delivery System for Improving Antipsychotic Activity of Risperidone
by: Liroy Lugasi, et al.
Published: (2020-09-01)

Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity
by: L. Lugasi, et al.
Published: (2020-10-01)

Sex differences in side effects of second-generation antipsychotics
by: Paterakis Perikles, et al.
Published: (2008-04-01)

Pancreatitis as a rare side effect of paliperidone use
by: Chien- Lin Wu, et al.
Published: (2020-01-01)

Validation of a quick and simple chromatographic method for simultaneous quantification of sertraline, escitalopram, risperidone and paliperidone levels in the human plasma
by: Jeremić Aleksandra, et al.
Published: (2021-01-01)

Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease
by: Guadalupe Rodriguez, et al.
Published: (2023-01-01)

Does risperidone seem safe in patients with antipsychotic-induced leukoneutropenia? Case report
by: W. Abid, et al.
Published: (2023-03-01)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
by: Shiraz Hussain, et al.
Published: (2021-01-01)